Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Clinical trial NCT02206763 · TERMINATED
Trial details
- NCT number
- NCT02206763
- Sponsor
- Sierra Oncology LLC - a GSK company
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-10-16
- Primary completion
- 2017-01-12
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.